LONG TERM OCULAR EFFECTS OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (RANIBIZUMAB) FOR RETINOPATHY OF PREMATURITY
2nd GLOBAL OPHTHALMOLOGY SUMMIT 2019
March 27-28, 2019 | Amsterdam, Netherlands
Nisreen Albalushi, Nasra Al-Habsi, Chandrashakir, Gupta Lokesh and Yousif Al-Ahmer
Oman Medical Specialty Board, Oman
Scientific Tracks Abstracts : Ophthalmol Case Rep
Abstract:
Objective of the study is to study the ocular and systemic effects of ranibizumab in patients with retinopathy of prematurity and to find out if any ocular and systemic side effects documented due to ranibizumab injection. The study is retrospective case series (from January 2014 to May 2016) and included all premature children with the diagnosis of ROP who received anti VEGF (lucentis) for ROP. The study was conducted in a tertiary hospital (AL-Nahdha Hospital) . Patient with leukocoria or with congenital eye anomaly were excluded from the study. Demographic data were collected which include; DOB, gender, birth weight, birth history, neonatal history (oxygen exposure), and type of ROP. The data were collected by reviewing patients’ files in the hospital information system (Al-Shifa). All the diagnoses of retinopathy of prematurity were collected. A well-designed data collection sheet was prepared using EpiData software to enter the data. It was found that all patients had regressed ROP except 8 patients (9.6%) in their six months follow ups while after one year follow up it was found that all patients had regressed ROP except two patients (2.4%) After six months follow up it was found that none of the patients had cataract, three patients (3.6%) had strabismus, five patients (6%) had myopia, one patient (1.2%) had amblyopia and one patient (1.2%) had retinal detachment. After one year follow up it was found that one patient (1.2%) had cataract, seven patients (8.4%) had strabismus, six patients (7.2%) had myopia, one patient (1.2%) had amblyopia and one patient (1.2%) had retinal detachment. No systemic complications were documented. In conclusion, Few cases from the study were found to have ocular side effects and no systemic side effects were reported. Ranibizumab intravitreal injection was found to be clinically effective in treating patients with retinopathy of prematurity.
Biography:
Nisreen Albalushi graduated from Oman Medical College in 2013 by the age of 25 years old and did her internship in obstetrics and gynecology, medicine and surgery. Worked as a medical officer in medicine and pediatrics from 2014 until she joined residency in ophthalmology program in Oman Medical Specialty Board. She is currently in her fourth year of residency which is the surgical year of the program. She had one poster presented in international conference of surgical glaucoma in Muscat-Oman: Glaucoma following congenital cataract surgery- case series from Al-Nahdha Hospital, a tertiary eye center in Oman.
E-mail: Nisreenasser87@gmail.com
PDF HTML